{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-123853","form_type":"8-K","ticker":"RIGL","cik":"0001034842","company_name":"RIGEL PHARMACEUTICALS INC","filed_at":"2022-12-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.331878+00:00","generated_at":"2026-06-21T10:02:28.939774+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"FDA approves Rigel's REZLIDHIA for mIDH1 relapsed/refractory AML","bullets":["FDA approved REZLIDHIA (olutasidenib) for adult patients with relapsed/refractory AML with IDH1 mutation.","Phase 2 trial showed 35% CR+CRh rate (51/147) with median duration of response 25.9 months.","Median time to CR or CRh was 1.9 months; 92% of responders achieved CR.","Rigel acquired exclusive worldwide license from Forma Therapeutics in August 2022.","Conference call and webcast today at 6:30 p.m. ET to discuss approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-123853","json":"https://secwatch.observer/filing/0001104659-22-123853.json","markdown":"https://secwatch.observer/filing/0001104659-22-123853.md","text":"https://secwatch.observer/filing/0001104659-22-123853.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1034842/000110465922123853/0001104659-22-123853-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1034842/000110465922123853/tm2231791d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T10:02:28.939774+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}